DJIA 16,790.19 13.76 0.08%
NASDAQ 4,748.36 -32.90 -0.69%
S&P 500 1,979.92 -7.13 -0.36%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

38.00 -3.79 (-9.07%)

REAL-TIME: Last trade at

Extended Hours: $38.00 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

SRPT $38.00 -9.07%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $40.01
Previous Close $41.79
Daily Range $35.77 - $40.68
52-Week Range $11.33 - $41.97
Market Cap $1.6B
P/E Ratio -11.26
Dividend (Yield) $0.00 (0.0%)
Volume 5,979,858
Average Daily Volume 1,881,538
Current FY EPS -$4.92




Drug Makers

Sarepta Therapeutics (SRPT) Description

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Website:

News & Commentary Rss Feed

Why Shares of Sarepta Therapeutics Inc Are Falling Today

A capital raise disappoints investors, sending shares lower.

Sarepta Therapeutics (SRPT) Stock Falls After Pricing Secondary Offering

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?

Which of these two companies will win the race to successfully develop the first Duchenne muscular dystrophy treatment? Our team of contributors weigh in.

Sarepta's Less-Than-Perfect Data

Give the drugmaker a pass on its historical control data.

Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

BioMarin Buys Back Kuvan Rights And Aims At Bigger Target

Sarepta Therapeutics (SRPT) Stock Spikes on Duchenne Muscular Dystrophy Study Data

Why Sarepta Therapeutics Shares Are Soaring Today

Sarepta has released positive efficacy and safety data relating to eteplirsen, its therapy for Duchenne muscular dystrophy.

See More SRPT News...

SRPT's Top Competitors

SRPT $38.00 (-9.07%)
Current stock: SRPT
AMGN $141.22 (-1.79%)
Current stock: AMGN
GILD $97.54 (-1.73%)
Current stock: GILD
BIIB $275.99 (-3.69%)
Current stock: BIIB